Costs of haematological adverse events in chronic myeloid leukaemia patients: A retrospective cost analysis of the treatment of anaemia, neutropenia and thrombocytopenia in patients with chronic myeloid leukaemia

Journal of Medical Economics

Volumn 12, Issue 2, 2009, Pages 164-169

  Bouwmans, Clazien ^a   Janssen, Jeroen ^b   Huijgens, Peter ^b   Uyl De Groot, Carin ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Anaemia; Chronic myeloid leukaemia; Costs; Neutropenia; Thrombocytopenia

Indexed keywords

ALPHA INTERFERON; BOSUTINIB; CIPROFLOXACIN; DASATINIB; ERYTHROPOIETIN; FLUCONAZOLE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMATINIB; LEVOFLOXACIN; NILOTINIB; PROTEIN TYROSINE KINASE INHIBITOR; TRANEXAMIC ACID;

ADULT; ANEMIA; ANTIBIOTIC PROPHYLAXIS; ARTICLE; CHRONIC MYELOID LEUKEMIA; DISEASE SEVERITY; ERYTHROCYTE TRANSFUSION; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; MALE; NETHERLANDS; NEUTROPENIA; RETROSPECTIVE STUDY; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA;

ADOLESCENT; ADULT; AGED; ANEMIA; ANTI-INFECTIVE AGENTS; ANTIFIBRINOLYTIC AGENTS; COHORT STUDIES; COSTS AND COST ANALYSIS; FEMALE; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MEDICAL AUDIT; MIDDLE AGED; NETHERLANDS; NEUTROPENIA; RETROSPECTIVE STUDIES; THROMBOCYTOPENIA; YOUNG ADULT;

EID: 67749099506     PISSN: 13696998     EISSN: None     Source Type: Journal    
DOI: 10.3111/13696990903149479     Document Type: Article

References (24)

1. Nowell P, Hungerford D. A minute chromosome in human chronic granulocytic leukemia. Science 1960;132:1497.
2. Nowell P. Discovery of the Philadelphia chromosome: a personal perspective. J Clin Invest 2007;117(8):2033-2035. (Pubitemid 47219542)
3. Heisterkamp N, Stephenson J, Groffen J, et al. Localization of the c-ab1 oncogene adjacent to a translocation break point in chronic myelocytic leukaemia. Nature 1983;306(5940):239-242. (Pubitemid 14232351)
4. Bartram C, de Klein A, Hagemeijer A, al. Translocation of c-ab1 oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia. Nature 1983;306(5940):277-280.
5. Sawyers C. Medical progress: chronic myeloid leukemia. N Engl J Med 1999;340(17):1330-1340. (Pubitemid 29407384)
6. O'Brien S, Guilhot F, Larson R, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronicphase chronic myeloid leukemia. N Engl J Med 2003;348(11):994-1004. (Pubitemid 36302244)
7. Atallah E, Kantarjian H, Cortes J. Emerging safety issues with imatinib and other Abl tyrosine kinase inhibitors. Clin Lymphoma Myeloma 2007;7(Suppl 3):S105-112 (Pubitemid 46848464)
8. Druker B, Talpaz M, Resta D, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001;344(14):1031-1037. (Pubitemid 32267972)
9. Druker B, Guilhot FF, O'Brien S, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006;355(23):2408-2417. (Pubitemid 44903745)
10. Liou S, Stephens J, Carpiuc K, et al. Economic burden of haematological adverse events in cancer patients. A systematic review. Clin Drug Invest 2007;27(6):381-396.
11. Oostenbrink J, Bouwmans C, Koopmanschap M, Rutten F. Handleiding voor kostenonderzoek. Methoden en standaardprijzen voor economische evaluaties [Guideline for cost research, methods and standard-cost prices for economic evaluations in health care] (in Dutch). Diemen: Health Care Insurance Board, 2004.
12. van Loenen A. (ed.) Farmacotherapeutisch Kompas. [ Pharmacotherapeutic Compass] (in Dutch). Houten: Bohn Stafleu van Loghum, 2003
13. Nederlandse Zorgautoriteit (Dutch Healthcare Authority). Available at: http://www.nza.nl.
14. Uyl-de Groot C, McDonnell J, Groen H, et al. Cost-effectiveness of new drugs in patients with phase IIIB-IV non-small cell lung cancer: results of a Markov chain model. Eur J Hosp Pharm Sci 2005;11:37-41.
15. Centraal Bureau voor de Statistiek (Statistics Netherlands). Consumer Price Index (CPI) all households 2000=100. 15 February 2007 (cited Hune 2007). Available at: http://statline.cbs.nl.
16. Kantarjian H, Talpaz M, O'Brien S, et al. Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results. Clin Cancer Res 2002;8(7):2177-2187. (Pubitemid 34753588)
17. Kantarjian H, Cortes J, O'Brien S, et al. Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferonalpha. Blood 2004;104(7):1979-1988. (Pubitemid 39297846)
18. Systematic review of the costs of hematologic adverse events in adult cancer patients treated with chemotherapy. ISPOR, 2006.
19. Herold M, Hieke K. Costs of toxicity during chemotherapy with CHOP, CHOP/CVP, and fludarabine. Eur J Health Econ 2002;3(3):166-172. (Pubitemid 36401999)
20. Annemans L, Giaccone G, Vergnenegre A. The cost-effectiveness of paclitaxel (Taxol) + cisplatin is similar to that of teniposide + cisplatin in advanced small-cell lung cancer: a multicountry analysis. Anticancer Drugs 1999;10(6):605-615. (Pubitemid 29410808)
21. Calhoun EA, Chang CH, Welshman EE, et al. Evaluating the total costs of chemotherapy-induced toxicity: results from a pilot study with ovarian cancer patients. Oncologist 2001;6(5):441-445.
22. Cantor S, Elting L, Jr DH, Rubenstein E. Pharmacoeconomic analysis of oprelvekin (recombinant human interleukin-11) for secondary prophylaxis of thrombocytopenia in solid tumor patients receiving chemotherapy. Cancer 2003;97(12):3099-3106. (Pubitemid 36676266)
23. Elting L, Cantor S, Martin C, et al. Cost of chemotherapy-induced thrombocytopenia among patients with lymphoma or solid tumors. Cancer 2003;97(6):1541-1550. (Pubitemid 36297784)
24. Malone D, Sullivan S, Black D, et al. The cost of treating chemotherapy-induced thrombocytopenia [abstract no. 887]. Proc Am Soc Clin Oncol 1995.